INTERNATIONAL SEARCH REPORT International application No. PCT/AU2015/050040 A. CLASSIFICATION OF SUBJECT MATTER C07D 311/58 (2006.01) C07D 311/16 (2006.01) C07D 407/04 (2006.01) Α61Κ 31/353 (2006.01) Α61Ρ 35/00 (2006.01) According to International Patent Classification (IPC) or to both national classification and IPC Β. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) REGISTRY, CAPLUS - structure search based on formula (I) Google Patents - NOVOGEN, chemoresistant cancer, ALVERO A., MOR G., HEATON A., BROWN D., KELLY G. and variations and combinations thereof C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* X Citation of document, with indication, where appropriate, of the relevant passages Documents are listed in the continuation of Box C Further documents are listed in the continuation of Box C X See patent family annex Relevant to claim No. "A" Special categories of cited documents: document defining the general state of the art which is not "T" later document published after the international filing date or priority date and not in "E” considered to be of particular relevance earlier application or patent but published on or after the "X" conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel "L" international filing date document which may throw doubts on priority claim(s) or ..γ,, or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to "0" which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family "p" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report 26 March 2015 26 March 2015 Name and mailing address of the ISA/AU Authorised officer AUSTRALIAN PATENT OFFICE Cassandra Smith ΡΟ BOX 200, WODEN ACT 2606, AUSTRALIA AUSTRALIAN PATENT OFFICE Email address: pct@ipaustralia.gov.au (ISO 9001 Quality Certified Service) Telephone No. +61 2 62223633 Form PCT/ISA/210 (fifth sheet) (July 2009) INTERNATIONAL SEARCH REPORT C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT International application No. PCT/AU2015/050040 Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A WO 2012/061409 Α1 (MARSHALL EDWARDS, INC) 10 May 2012 formula (II), table 1, examples, paragraph [0016] 1-59 A US 2012/0251630 Α1 (ALVERO et al.) 04 October 2012 formula (I) and (II), examples, paragraph [0020] 1-59 A WO 2005/049008 Al (NOVOGEN RESEARCH ΡΤΥ LTD) 02 June 2005 formula (I) and (VI), compounds 31-44, examples 1-59 A WO 2006/032086 Al (NOVOGEN RESEARCH ΡΤΥ LTD) 30 March 2006 formula (I), page 13-16 1-59 A WO 1998/018773 Al (NOVO NORDISK A/S) 07 May 1998 formula (I), page 11-17, examples 1-59 Form PCT/ISA/210 (fifth sheet) (July 2009) INTERNATIONAL SEARCH REPORT International application No. Information on patent family members PCT/AU2015/050040 This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information. Patent Document/s Cited in Search Report Patent Family Member/s Publication Number Publication Date Publication Number Publication Date WO 2012/061409 Α1 10 May 2012 CA 2816319 Α1 10 May 2012 CA 2816322 Α1 10 May 2012 ΕΡ 2635121 Α1 11 Sep 2013 ΕΡ 2635273 Α2 11 Sep 2013 JP 2013541563 A 14 Nov 2013 US 2013273177 Α1 17 Oct 2013 US 2014234295 Α1 21 Aug 2014 WO 2012061413 Α2 10 May 2012 US 2012/0251630 Α1 04 October 2012 WO 2005/049008 Α1 02 June 2005 AU 2004290465 Α1 02 Jun 2005 AU 2004290465 Β2 AU 2005201855 Α1 AU 2005201855 Β2 AU 2005287865 Α1 AU 2005287865 Β2 CA 2506238 Α1 CA 2542351 Α1 CA 2581316 Α1 CN 101056868 A CN 101056868 Β CN 101094844 A CN 101094844 Β CN 101123958 A ΕΡ 1686981 Α1 ΕΡ 1794141 Α1 ΕΡ 1794141 Β1 ΕΡ 1809618 Α1 ΕΡ 1809618 Β1 ΕΡ 2407462 Α1 ΕΡ 2407462 Β1 ΕΡ 2436680 Α2 ΗΚ 1108685 Α1 ΗΚ 1112617 Α1 IL 182034 A IL 182042 A 11 Mar 2010 06 Apr 2006 29 Mar 2012 30 Mar 2006 16 Feb 2012 21 Mar 2006 02 Jun 2005 30 Mar 2006 17 Oct 2007 02 May 2012 26 Dec 2007 25 Jul 2012 13 Feb 2008 09 Aug 2006 13 Jun 2007 09 Nov 2011 25 Jul 2007 17 Jul 2013 18 Jan 2012 30 Jul 2014 04 Apr 2012 08 Feb 2013 26 Apr 2013 31 Oct 2012 29 Mar 2012 Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001. INTERNATIONAL SEARCH REPORT Information on patent family members International application No. PCT/AU2015/050040 This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information. Patent Document/s Cited in Search Report Publication Number Publication Date Patent Family Member/s Publication Number Publication Date JP 2008513376 A 01 May 2008 JP 4913056 Β2 11 Apr 2012 JP 2006096734 A 13 Apr 2006 jp 4976649 Β2 18 Jul 2012 JP 2007525485 A 06 Sep 2007 JP 2012144537 A 02 Aug 2012 JP 2014237638 A 18 Dec 2014 MX ΡΑ06005697 A 17 Aug 2006 MX 2007003215 A 21 Jan 2008 MX 2007003216 A 10 Mar 2008 NO 20062876 A 08 Aug 2006 NO 20071578 A 30 May 2007 NO 20072004 A 30 May 2007 ΝΖ 546150 A 30 Apr 2010 ΝΖ 553834 A 26 Mar 2010 ΝΖ 553835 A 26 Mar 2010 US 2006074127 Α1 06 Apr 2006 US 7601855 Β2 13 Oct 2009 US 2006074126 Α1 06 Apr 2006 US 8080675 Β2 20 Dec 2011 US 2009317490 A1 24 Dec 2009 US 8084628 Β2 27 Dec 2011 US 2012004296 A1 05 Jan 2012 US 8163795 Β2 24 Apr 2012 US 2012172424 Α1 05 Jul 2012 US 8461361 Β2 11 Jun 2013 US 2012114766 Α1 10 May 2012 US 8697891 Β2 15 Apr 2014 US 2014161908 Α1 12 Jun 2014 US 8957109 Β2 17 Feb 2015 US 2006167037 Α1 27 Jul 2006 US 2014170243 Α1 19 Jun 2014 WO 2006032085 Α1 30 Mar 2006 WO 2006032086 Α1 30 Mar 2006 Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001. INTERNATIONAL SEARCH REPORT International application No. Information on patent family members PCT/AU2015/050040 This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information. Patent Document/s Cited in Search Report Patent Family Member/s Publication Number Publication Date Publication Number Publication Date WO 2006/032086 Α1 30 March 2006 AU 2004290465 A1 02 Jun 2005 AU 2004290465 Β2 11 Mar 2010 AU 2005201855 Α1 06 Apr 2006 AU 2005201855 Β2 29 Mar 2012 AU 2005287865 Α1 30 Mar 2006 AU 2005287865 Β2 16 Feb 2012 CA 2506238 Α1 21 Mar 2006 CA 2542351 Α1 02 Jun 2005 CA 2581316 Α1 30 Mar 2006 CN 101056868 A 17 Oct 2007 CN 101056868Β 02 May 2012 CN 101094844 A 26 Dec 2007 CN 101094844 Β 25 Jul 2012 CN 101123958 A 13 Feb 2008 ΕΡ 1686981 Α1 09 Aug 2006 ΕΡ 1794141 Α1 13 Jun 2007 ΕΡ 1794141 Β1 09 Nov 2011 ΕΡ 1809618 Α1 25 Jul 2007 ΕΡ 1809618 Β1 17 Jul 2013 ΕΡ 2407462 Α1 18 Jan 2012 ΕΡ 2407462 Β1 30 Jul 2014 ΕΡ 2436680 Α2 04 Apr 2012 ΗΚ 1108685 Α1 08 Feb 2013 ΗΚ 1112617 Α1 26 Apr 2013 IL 182034 A 31 Oct 2012 IL 182042 A 29 Mar 2012 JP 2008513376 A 01 May 2008 JP 4913056 Β2 11 Apr 2012 JP 2006096734 A 13 Apr 2006 jp 4976649 Β2 18 Jul 2012 JP 2007525485 A 06 Sep 2007 JP 2012144537 A 02 Aug 2012 JP 2014237638 A 18 Dec 2014 MX ΡΑ06005697 A 17 Aug 2006 MX 2007003215 A 21 Jan 2008 Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001. INTERNATIONAL SEARCH REPORT International application No. Information on patent family members PCT/AU2015/050040 This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information. Patent Document/s Cited in Search Report Patent Family Member/s Publication Number Publication Date Publication Number Publication Date MX 2007003216 A 10 Mar 2008 NO 20062876 A 08 Aug 2006 NO 20071578 A 30 May 2007 NO 20072004 A 30 May 2007 ΝΖ 546150 A 30 Apr 2010 ΝΖ 553834 A 26 Mar 2010 ΝΖ 553835 A 26 Mar 2010 US 2006074127 Α1 06 Apr 2006 US 7601855 Β2 13 Oct 2009 US 2006074126 Α1 06 Apr 2006 US 8080675 Β2 20 Dec 2011 US 2009317490 A1 24 Dec 2009 US 8084628 Β2 27 Dec 2011 US 2012004296 A1 05 Jan 2012 US 8163795 Β2 24 Apr 2012 US 2012172424 Α1 05 Jul 2012 US 8461361 Β2 11 Jun 2013 US 2012114766 Α1 10 May 2012 US 8697891 Β2 15 Apr 2014 US 2014161908 Α1 12 Jun 2014 US 8957109 Β2 17 Feb 2015 US 2006167037 Α1 27 Jul 2006 US 2014170243 Α1 19 Jun 2014 WO 2005049008 Α1 02 Jun 2005 WO 2006032085 Α1 30 Mar 2006 WO 1998/018773 A1 07 May 1998 AU 4700097 A 22 May 1998 CA 2270113 Α1 07 May 1998 ΕΡ 0937058 Α1 25 Aug 1999 JP 2001502705 A 27 Feb 2001 NO 992010 A 25 Jun 1999 US 6043269 A 28 Mar 2000 ΖΑ 9709642 A 28 Apr 1998 End of Annex Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001. 1. A compound of the general formula (I)or a pharmaceutically acceptable salt, hydrate, derivative, solvate or prodrug thereof, wherein:R1 is selected from the group consisting of: Η and CrC6 alkyl,R2 is selected from the group consisting of: OH and CrC6 alkoxy,R3is selected from the group consisting of: Η, Ci-C6 alkyl and halo,R10 to R12 are independently selected from the group consisting of: OH, Ci-C6 alkyl, CrC6 alkoxy and halo,R13 is selected from the group consisting of: OH, CrC6 alkoxy, NH2, ΝΗΜ℮, NHEt, N(Me)2 and N(Et)2,R14 and R15 are independently selected from the group consisting of: Η, OH, Ci-C6 alkyl and halo, orR13 and one of R14 and R15 form the following structure:0X / 2. The compound of claim 1, wherein R1 is selected from the group consisting of: Η and C1-C3 alkyl. 3. The compound of claim 1 or claim 2, wherein R2 is OH or ΟΜ℮. 4. The compound of claim 3, wherein R2 is OH. 5. The compound of any one of claims 1 to 4, wherein R3 is selected from the group consisting of: Η, C1-C3 alkyl and halo. 6. The compound of claim 5, wherein R3 is selected from the group consisting of: Η, C1-C3 alkyl, F and Cl. 7. The compound of any one of claims 1 to 6, wherein R10 is selected from the group consisting of: OH, ΟΜ℮ and halo. 8. The compound of claim 7, wherein R10 is selected from the group consisting of: OH, ΟΜ℮, F and Cl. 9. The compound of claim 8, wherein R10 is selected from the group consisting of: OH, ΟΜ℮ and F. 10. The compound of claim 9, wherein R10 is OH. 11. The compound of any one of claims 1 to 10, wherein R11 and R12 are independently selected from the group consisting of: OH, ΟΜ℮, C1-C4 alkyl and F. 12. The compound of claim 11, wherein R11 and R12 are independently selected from the group consisting of: OH, ΟΜ℮, /erf-butyl, methyl and F. 13. The compound of claim 12, wherein R11 and R12are independently selected from the group consisting of: ΟΜ℮, /erf-butyl, methyl and F. 14. The compound of claim 12, wherein R11 and R12are independently selected from the group consisting of: ΟΜ℮, /erf-butyl, and F. 15. The compound of any one of claims 1 to 14, wherein R13 is selected from the group consisting of: OH, ΟΜ℮, NH2, NHEt and N(Et)2. 16. The compound of claim 15, wherein R13 is OH. 17. The compound of any one of claims 1 to 16, wherein R14 and R15 are independently selected from the group consisting of: Η, F, Cl and methyl. 18. The compound of any one of claims 1 to 14, wherein R13 and one of R14 and R15 form the following structure:X /0 ■>U0 19. A compound of formula (I) having the following structure:(la)wherein R1, R3 and R10 to R15 are as defined in any one of claims 1 to 18. 20. The compound of claim 19, wherein R1 is selected from the group consisting of: Η and C1-C3 alkyl. 21. The compound of claim 19 or claim 20, wherein R3 is selected from the group consisting of: Η, C1-C3 alkyl, F and Cl. 22. The compound of any one of claims 19 to 21, wherein R10 is selected from the group consisting of: OH, ΟΜ℮ and F. 23. The compound of any one of claims 19 to 22, wherein R11 is selected from the group consisting of: terf-butyl, ΟΜ℮, methyl and F. 24. The compound of any one of claims 19 to 23, wherein R12 is selected from the group consisting of: ΟΜ℮, /erf-butyl, methyl and F. 25. The compound of any one of claims 19 to 22, wherein R11 and R12 are independently selected from the group consisting of: ΟΜ℮, /erf-butyl and F. 26. The compound of any one of claims 19 to 25, wherein R13 is selected from the group consisting of: OH, ΟΜ℮, NH2, NHEt and NEt2. 27. The compound of claim 26, wherein R13 is OH. 28. The compound of any one of claims 19 to 27, wherein R14 and R15 are independently selected from the group consisting of: Η, F, Cl and methyl. 29. The compound of any one of claims 19 to 25, wherein R13 and one of R14 and R15 form the following structure:X , Ο ■>Uo 31. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 30 together with a pharmaceutically acceptable carrier, diluent or excipient. 32. A method for the treatment of cancer in a subject in need thereof, the method comprising administration to the subject of a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 30, or a composition according to claim 31, and wherein the cancer is a solid tumour. 33. The method of claim 32, wherein the cancer is a cancer that has recurred. 34. The method of claim 32 or claim 33, wherein the cancer is resistant to one or more chemotherapeutic agents. 35. The method of any one of claims 32 to 34, wherein the cancer is selected from the group consisting of: pancreatic cancer, colorectal cancer, melanoma, prostate cancer, brain cancer (including paediatric and adult), ovarian cancer, breast cancer, lung cancer, liver cancer, uterine cancer, neuroblastoma, mesothelioma, malignant ascites or peritoneal cancer. 36. The method of claim 35, wherein the cancer is ovarian cancer. 37. The method of claim 35, wherein the cancer is brain cancer. 38. The method of claim 37, wherein the brain cancer is glioma. 39. The method of claim 35, wherein the cancer is prostate cancer. 40. The method of claim 35, wherein the cancer is neuroblastoma. 41. The method of claim 35, wherein the cancer is liver cancer. 42. The method of any one of claims 36 to 38, wherein the compound is selected from the group consisting of compounds 2, 6, 9 and 13.25710778ν1 CORFIEM 43. The method of claim 39, wherein the compound is compound 33 or compound 36. 44. The method of claim 40, wherein the compound is compound 9 or compound 36. 45. The method of claim 41, wherein the compound is compound 20 or compound 33. 46. A method for reducing incidences of, or risk of, cancer recurrence in a subject deemed to be at risk of cancer recurrence, the method comprising administration to the subject of an effective amount of a compound of formula (I) according to any one of claims 1 to 30, or a composition according to claim 31. 47. The method of claim 46, wherein the subject deemed to be at risk of cancer recurrence is a subject who is in cancer remission. 48. The method of claim 47, wherein the subject is in remission from ovarian cancer or brain cancer. 49. A method for inducing apoptosis in, or inhibiting the proliferation of, a cancer stem cell, the method comprising contacting the cancer stem cell with an effective amount of a compound of formula (I) according to any one of claims 1 to 30. 50. The method of claim 49, wherein the cancer stem cell is an ovarian cancer stem cell or a brain cancer stem cell. 51. A method for treating a disease in a subject caused by cancer stem cells, the method comprising administration to the subject of a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 30, or a composition according to claim 31. 52. The method of claim 51, wherein the disease is cancer. 53. The method of claim 52, wherein the cancer is a metastatic cancer. 54. The method of any one of claims 51 to 53, wherein the stem cells are ovarian cancer stem cells or brain cancer stem cells. 55. The method of any one of claims 46 to 54, wherein the compound is selected from the group consisting of compounds 2, 6, 9 and 13. 56. The method of claim 55, wherein the compound is compound 2 or compound 9. 57. A method for preparing a compound of the formula (I) as defined in claim 1 comprising the steps of:(a) reducing a compound of formula (II) to produce a compound of formula (III):wherein in the compound of formula (II) R1, R3, and R10 to R15 are as defined in claim 1, and R2 is OAc or as defined in claim 1, and in the compound of formula (III) R1 to R3 and R10 to R15 are as defined in claim 1, and(b) hydrogenating a compound of formula (III) to produce a compound of formula (I),wherein R1 to R3, and R10 to R15 are as defined in claim 1. 58. The method of claim 57, wherein step (a) is carried out by reacting a compound of formula (II) with a borane reagent. 59. The method of claim 57 or claim 58, wherein step (b) is carried out by reacting a compound of formula (III) with a heterogenous metal catalyst under an atmosphere of hydrogen.